

Complex Menopause Clinic B4-4500 Oak St. Vancouver, BC V6H-3N1 T: 604.875.2322 F: 604.675-2652

		Date of Referral:
		New Patient □
Patient Name:	PHN (Personal H	Health Number):
Address:	DD/MM/YYYY):Primary Phone N	umber:
Date of Birth (DD/MM/YYYY):	
Email:	☐ Consent to contact by email	
Referring Prov	ider:MSP# Provider (if different from referring)	☐ Specialist ☐ GP ☐ Other
Primary Care F	Provider (if different from referring)	
Who agrees to	continue care? ☐ Referring Provider ☐ Primary	Care Provider
	nt identify as Indigenous (First Nations, Metis, Inuit)? er required? □ Yes □ No Language Required:	
	nt prefer to attend the appointment: □ Virtual □ In Pe	
Inclusion C	riteria	
at had promote	ire menopause/POI < age 40.	
nt nau prematu	ne menopause/FOI > age 40.	
of last menstrua	l period (MM/DD/YYYY):	
recent FSH resu	ult and date (required):e contraindications to hormone therapy, limiting r	management entions. Please check the
	ow and provide supporting documentation (requir	
·		
	history of estrogen-dependent cancers (eg. Breast, Egrartery disease	endometrial, Ovarian)
☐ Active or	previous personal history of stroke, TIA, MI, or VTE	
☐ Acute live	er disease (not including fatty liver disease)	
☐ Acute live☐ Inherited	er disease (not including fatty liver disease) high risk of VTE (eg. Thrombophilia)	
☐ Acute live☐ Inherited	er disease (not including fatty liver disease)	ntibodies
☐ Acute live ☐ Inherited ☐ Systemic ased cancer ris	er disease (not including fatty liver disease) high risk of VTE (eg. Thrombophilia) lupus erythematosus (SLE) <u>with</u> anti-phospholipid an sk: Patient is a carrier of Hereditary Cancer Syndro (s) that has been confirmed through genetic testing	ome with increased risk of breast or
☐ Acute live ☐ Inherited ☐ Systemic ased cancer ris	er disease (not including fatty liver disease) high risk of VTE (eg. Thrombophilia) lupus erythematosus (SLE) <u>with</u> anti-phospholipid an	ome with increased risk of breast or
☐ Acute live ☐ Inherited ☐ Systemic ased cancer ris cologic cancer ons, established	er disease (not including fatty liver disease) high risk of VTE (eg. Thrombophilia) lupus erythematosus (SLE) <u>with</u> anti-phospholipid an sk: Patient is a carrier of Hereditary Cancer Syndro (s) that has been confirmed through genetic testing	ome with increased risk of breast or ng or is at high risk for cancer for other
☐ Acute live ☐ Inherited ☐ Systemic ased cancer riscologic cancer ons, established e of condition/ge of reports/supports cancers include	er disease (not including fatty liver disease) high risk of VTE (eg. Thrombophilia) lupus erythematosus (SLE) with anti-phospholipid an ek: Patient is a carrier of Hereditary Cancer Syndro (s) that has been confirmed through genetic testind d with a risk assessment tool:	ome with increased risk of breast or ng or is at high risk for cancer for other associated with hereditary breast and/or PALB2, TP53, PTEN, STK11, and CDH1.
☐ Acute live ☐ Inherited ☐ Systemic ased cancer riscologic cancer ons, established e of condition/ge of reports/support an cancers include e see this docur	er disease (not including fatty liver disease) high risk of VTE (eg. Thrombophilia) lupus erythematosus (SLE) with anti-phospholipid and sk: Patient is a carrier of Hereditary Cancer Syndro (s) that has been confirmed through genetic testing d with a risk assessment tool: ne mutation: prting evidence included (required): High-risk genes a de the BRCA1 or BRCA2 gene mutation, as well as F	ome with increased risk of breast or ng or is at high risk for cancer for other associated with hereditary breast and/or PALB2, TP53, PTEN, STK11, and CDH1. In the risk: HCP Guidelines Manuals HBOC.pdf
□ Acute live □ Inherited □ Systemic ased cancer riscologic cancer ons, established e of condition/ge of reports/support an cancers include e see this docur	er disease (not including fatty liver disease) high risk of VTE (eg. Thrombophilia) lupus erythematosus (SLE) with anti-phospholipid and ek: Patient is a carrier of Hereditary Cancer Syndro (s) that has been confirmed through genetic testing d with a risk assessment tool: ne mutation: orting evidence included (required): High-risk genes a de the BRCA1 or BRCA2 gene mutation, as well as P ment for more information on who is considered at hig used and results:	ome with increased risk of breast or ng or is at high risk for cancer for other associated with hereditary breast and/or PALB2, TP53, PTEN, STK11, and CDH1. In the risk: HCP Guidelines Manuals HBOC.pdf
□ Acute live □ Inherited □ Systemic ased cancer ris cologic cancer ons, established of condition/ge of reports/support on cancers include e see this docur	er disease (not including fatty liver disease) high risk of VTE (eg. Thrombophilia) lupus erythematosus (SLE) with anti-phospholipid and sk: Patient is a carrier of Hereditary Cancer Syndro (s) that has been confirmed through genetic testing d with a risk assessment tool: ne mutation: orting evidence included (required): High-risk genes and the BRCA1 or BRCA2 gene mutation, as well as Perment for more information on who is considered at high used and results: >20-25 % using IBIS or BCRAT models	ome with increased risk of breast or ng or is at high risk for cancer for other associated with hereditary breast and/or PALB2, TP53, PTEN, STK11, and CDH1. In the risk: HCP GuidelinesManuals HBOC.pdf

Patient has a spinal cord injury and is experiencing menopausal symptoms.				
Level of injury:				
Mobility aids used and frequency:				
Patient has HIV and is experiencing menopausal symptoms.				
Patient is a cancer survivor whose therapy has affected ovarian function.				
Type of cancer: Type of treatment(s) and duration:				
Patient is currently experiencing systemic menopausal symptoms (e.g., hot flushes, night sweats) t responded to usual management. Please specify which symptoms and which treatments have been (required):				
Symptoms: Changes to periods Hot flashes or night sweats Vaginal dryness or pain/dyspareunia Bladder issues, incontinence Sleep disturbance Mood disturbance, irritability and anxiety				
Treatments previously tried: Oral contraceptive pills Progestin-only treatments Systemic estrogen (with or without progestin) therapy, Duavive, or Tibella SSRI/SNRI (i.e. Venlafaxine) Gabapentin Oxybutynin Fezolinetant/Elinzanetant				
Patient is experiencing Genitourinary Syndrome of Menopause (GSM) that has not responded to us management, without vulvar dystrophy. Indicate all treatments that have been tried (required):	ual			
 □ Vulvar moisturizers □ Vaginal moisturizers □ Lubricants □ Vaginal estrogen □ Systemic hormone therapy 				
Other Indication: (May include patients with multiple comorbidities. Please explain in detail below a relevant documentation).	nd pro	ovide		
relevant documentation).				
Please include the following: diagnostic and lab tests below, if not available in CST:	Yes	N/A		
Previous consultations/clinic notes regarding menopausal concerns or relevant issues.				
Pap/HPV test report				
Mammography report				
Bone Mineral Density scan				
FIT test/Colonoscopy report				

Exclusion Criteria

- · Patient currently not a BC resident
- Patient was assigned male at birth
- Patient does not have a care provider (MD or NP) for ongoing follow-up care.
- Post-menopausal bleeding/abnormal uterine bleeding not yet assessed (refer to community gynecologist).
- Patient has already been seen in the CMC and has been discharged. In these cases, we may provide provider-to-provider consultations. Please contact the clinic.
- Patient does not consent to having their visit/consult documented on EMR/CST Cerner
- ***Isolated complaints including but not limited to urinary incontinence, low libido, midlife weight gain, vulvar issues, or mental health issues. ***
- Patients who are under the care of an endocrinologist or gynecologist may be referred by their specialist, if needed. In this case, we will most likely want to arrange a provider-to-provider consult. Please provide more detail if you feel a referral is still needed.
- This is an urgent request please refer to ER or UC as appropriate.

Violence screening						
	_					
Does this patient have a history of aggression?	Yes □	No □				
If yes:	Verbal □	Physical □				
Please provide a brief description of the history of verbal and/or physical aggression incidents, outcomes and date of last occurrence (e.g. throwing objects, hitting someone, yelling).						
Effective Intervention(s)						